The Canadian Cancer Society (CCS) released a list of Top 10 research discoveries of 2011 that changed the landscape of cancer research. Included in this list were OCI and TGRI Senior Scientist Dr. John Dick and OCI Senior Scientist Dr. Gang Zheng.

Coming February 6, 2012, Research Support Services (RSS) will facilitate your clinical research approvals with the introduction of the new Coordinated Approval Process for Clinical Research (CAPCR). 

CAPCR is a web application which allows researchers to submit applications for approval within departments at UHN  (e.g., Grants and Contracts, Research Ethics Board, Research Facilities Planning, Investigational Drug Services, etc.), as well as departments, groups and committees throughout UHN that support research involving human subjects (e.g., Medical Engineering, CRDAC, Imaging, etc).  Submitting through this web application will ensure that you have all the UHN required approvals to conduct your clinical research.

For more information about this initiative, please contact the CAPCR Office at capcr@uhnresearch.ca.  Visit the Research Event Calendar for upcoming Information Sessions and Training Sessions.

The findings of a clinical trial, published in the prestigious journal The Lancet by OCI Clinician-Scientist Dr. Neil Fleshner, regarding the use of the drug dutasteride in low-risk prostate cancer have shown promising results in delaying disease progression.